A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome
- PMID: 28664561
- DOI: 10.1111/jir.12390
A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome
Abstract
Goal: To examine dementia characteristics, age at onset and associated co-morbidities in persons with Down syndrome.
Method: A total of 77 people with Down syndrome aged 35 years and older were followed up from 1996 to 2015. The diagnosis of dementia was established using the modified ICD 10 Criteria and a combination of objective and informant-based tests. Cognitive tests included the Test for Severe Impairment and the Down Syndrome Mental Status Examination; adaptive behaviour was measured using the Daily Living Skills Questionnaire, and data from the Dementia Questionnaire for People with Intellectual Disabilities have been available since 2005.
Results: Over the 20-year period, 97.4% (75 of 77) persons developed dementia with a mean age of dementia diagnosis of 55 years (SD = 7.1, median = 56 years). Clinical dementia was associated with cognitive and function decline and seizure activity. Risk for dementia increased from 23% in those aged 50 years to 80% in those aged 65 years and above. There were no differences by level of ID.
Conclusion: The previously reported high risk levels for dementia among people with Down syndrome were confirmed in this data as was the relationship with late onset epilepsy. The value of the instruments utilised in tracking decline and helping to confirm diagnosis is further highlighted.
Keywords: Down syndrome; dementia; longitudinal.
© 2017 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd.
Similar articles
-
A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome.J Intellect Disabil Res. 2014 Jan;58(1):61-70. doi: 10.1111/jir.12074. Epub 2013 Jul 31. J Intellect Disabil Res. 2014. PMID: 23902161
-
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years.JAMA Neurol. 2019 Feb 1;76(2):152-160. doi: 10.1001/jamaneurol.2018.3616. JAMA Neurol. 2019. PMID: 30452522 Free PMC article.
-
Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology.J Intellect Disabil Res. 2007 Jun;51(Pt. 6):463-77. doi: 10.1111/j.1365-2788.2006.00902.x. J Intellect Disabil Res. 2007. PMID: 17493029
-
Dementia and mortality in persons with Down's syndrome.J Intellect Disabil Res. 2006 Oct;50(Pt 10):768-77. doi: 10.1111/j.1365-2788.2006.00842.x. J Intellect Disabil Res. 2006. PMID: 16961706 Review.
-
Supporting advanced dementia in people with Down syndrome and other intellectual disability: consensus statement of the International Summit on Intellectual Disability and Dementia.J Intellect Disabil Res. 2018 Jul;62(7):617-624. doi: 10.1111/jir.12500. Epub 2018 May 20. J Intellect Disabil Res. 2018. PMID: 29781149
Cited by
-
Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid.Alzheimers Dement. 2024 Aug;20(8):5570-5577. doi: 10.1002/alz.14068. Epub 2024 Jun 28. Alzheimers Dement. 2024. PMID: 38940611 Free PMC article.
-
Characterization of white matter hyperintensities in Down syndrome.Alzheimers Dement. 2024 Sep;20(9):6527-6541. doi: 10.1002/alz.14146. Epub 2024 Aug 1. Alzheimers Dement. 2024. PMID: 39087352 Free PMC article.
-
Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.JAMA Neurol. 2022 Jun 1;79(6):565-574. doi: 10.1001/jamaneurol.2022.0983. JAMA Neurol. 2022. PMID: 35532913 Free PMC article. Clinical Trial.
-
PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.Neuroimage. 2021 Mar;228:117728. doi: 10.1016/j.neuroimage.2021.117728. Epub 2021 Jan 7. Neuroimage. 2021. PMID: 33421595 Free PMC article.
-
Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.Lancet. 2020 Jun 27;395(10242):1988-1997. doi: 10.1016/S0140-6736(20)30689-9. Lancet. 2020. PMID: 32593336 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical